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Given a commodity available at different prices, a unit-price account of choice predicts preference for
the cheaper alternative. This experiment determined if rhesus monkeys preferred remifentanil (an
ultra-short-acting m-opioid agonist) delivered at a lower unit price over a higher-priced remifentanil
alternative (Phases 1 and 3). Choice between equal-priced alternatives also was assessed (Phase 2). A
discrete-trials procedure was arranged in which three monkeys chose between two remifentanil
alternatives by responding on one of two levers. Different prices were arranged by manipulating drug
dose (0.3 and 0.1 mg/kg/injection) and/or the ratio requirement. Monkeys usually chose the larger-
dose alternative even when it was more expensive. Only when unit prices were relatively high (e.g., large
response requirements) did monkeys choose the cheaper (or equally priced) smaller-dose alternative.
Employing larger doses (0.9 and 0.3 mg/kg/injection) attenuated the larger-dose preference. The
results demonstrate that choice was not determined simply by unit price. An alternative model that
employs demand-function analysis to generate choice predictions is proposed.
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_______________________________________________________________________________
On fixed-ratio (FR) schedules of reinforce-
ment, the unit-price concept of behavioral
economics may help understand choice of
a single drug available at different doses and
response requirements. Unit price is defined
as a ratio of costs over benefits (e.g., Hursh,
Raslear, Shurtleff, Bauman, & Simmons, 1988)
in which cost variables are represented by the
FR requirement and benefits are associated
with the reinforcer magnitude or dose (Bickel,
DeGrandpre, Higgins, & Hughes, 1990;
Hursh, 2000). The unit price of a drug re-
inforcer can be expressed as:
Unit Price ~ FR=Dose: ð1Þ
Note that the unit price of a drug can be
manipulated by changing the FR, the dose, or
both.
Given a choice between a single commodity
available at different unit prices, the lower-
priced alternative should be chosen exclusively
(Becker, 1971; Samuelson & Nordhaus, 1985).
This hypothesis generally has been confirmed
in studies using appetitive reinforcers (Green,
Rachlin, & Hanson, 1983; Herrnstein & Love-
land, 1975; Neuringer, 1967). Studies investi-
gating choice of a drug at different doses, but
at the same FR requirement, have shown near-
exclusive choice of a larger (and cheaper)
dose of cocaine, methylphenidate (Johanson
& Schuster, 1975), or ethanol (Stewart, Wang,
Bass, & Meisch, 2002) over a smaller dose of
the same drug. In these studies, however, it is
not clear if choice was determined by unit
price or by dose. For example, would subjects
choose the smaller-dose alternative if it was the
cheaper alternative?
Madden, Bickel, and Jacobs (2000) investi-
gated human smokers’ choice of cigarette
puffs available at a range of unit prices.
Whereas subjects typically chose the lower-
priced alternative, in some comparisons sub-
jects chose the alternative associated with the
larger number of cigarette puffs even though
it was slightly more expensive than the smaller-
puff alternative. When unit prices were equal,
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subjects usually preferred a larger number of
puffs available at a larger FR over the smaller-
puff alternative available at a smaller FR.
Interestingly, at extremely high prices (ar-
ranged by increasing the FR of both alter-
natives) subjects reversed preference and
selected the smaller-puff (and smaller-FR)
alternative.
Anderson and Woolverton (2003) obtained
similar results in a self-control procedure
investigating cocaine choice in rhesus mon-
keys. Monkeys demonstrated near-exclusive
choice for the larger dose of cocaine
(0.1 mg/kg/inj) delayed by 30 s over a smaller
dose (0.03 mg/kg/inj) delayed by 10 s. Al-
though Anderson and Woolverton did not
present their results within an economic
framework, note that if delay is used as the
cost variable then the two alternatives were
equally priced. At longer delays (810 vs. 270 s)
a preference reversal was obtained; monkeys
chose the alternative associated with the
smaller dose and shorter delay. The results of
these two studies suggest that choice is more
determined by drug dose at lower prices and
by the response requirement (or delay) at
higher prices.
Unit-price predictions of choice have not
been assessed using opioid reinforcers. In the
present study, we investigated choice in rhesus
monkeys trained to self-administer remifenta-
nil, an ultra-short-acting m-opioid agonist use-
ful in surgical procedures (Glass, Gan, &
Howell, 1999; Rosow, 1999). Previous research
in our laboratory has demonstrated that the
reinforcing functions of remifentanil are
similar to those of the longer-acting opioids
alfentanil and fentanyl (Ko, Terner, Hursh,
Woods, & Winger, 2002). We chose to use
remifentanil to minimize drug accumulation
across choice opportunities. We selected an
intertrial interval (ITI) of 60 s because pilot
work demonstrated that doses of 0.1 and
0.3 mg/kg/inj (used in the majority of this
study) maintained similar response rates at an
FR 10 (i.e., there were no rate-suppressing
effects of the larger dose).
There were two major purposes of the
research. First, we wanted to ascertain if
predictions based on unit price could accu-
rately account for rhesus monkeys’ choice of
remifentanil available at different doses and
FR requirements. Second, we wanted to
examine remifentanil choice when the two
alternatives were equally priced but composed
of different FR and dose combinations. We
investigated remifentanil choice across a range
of unit prices in Phase 1. Several comparisons
dissociated choice predictions based on drug
dose from predictions based on unit price.
In Phase 2, we investigated choice between
equally priced alternatives. In Phase 3, the unit
price of the smaller-dose alternative was held
constant and the unit price of the larger-dose
alternative was progressively increased.
METHODS
Subjects
The subjects were 3 adult rhesus monkeys
(Macaca mulatta), 2 male (Monkeys 3572 and
3603) and 1 female (Monkey 3600), with
a history of drug self-administration including
remifentanil. Monkeys lived in the experimen-
tal chambers and were fed 10 to 15 Purina
monkey chow biscuits twice daily (at least
1.5 hr before experimental sessions) to main-
tain their body weights. Daily fresh fruit and
other treats supplemented this diet. Water
was continuously available. In accordance with
institutional animal care and use require-
ments, environmental enrichment toys also
were provided on a regular rotating basis.
Apparatus
Monkeys were permanently housed in stain-
less steel cages (83.3-cm long by 76.2-cm wide
by 91.4-cm deep). The front, top, and bottom
of the cage were made of barred stainless steel,
and a pan was located below the floor to
collect waste. Located on the wall to the left of
the barred front door was an intelligence
panel 20 cm in length and 15.4 cm in height,
approximately 10 cm from the front and
19 cm from the bottom of the cage. Across
the top of the stimulus panel, 1.5 cm apart,
were three circular openings, 2.5 cm in di-
ameter, covered with translucent plastic and
capable of being illuminated from behind with
5-W colored bulbs. The two side lights could
be illuminated red and the center light green.
Centered below the right and left stimulus
lights were response levers (Model 121-07,
BRS-LVE) capable of being operated by 10 to
15 g (0.10–0.15 N) of force. A 0.3-cm thick
stainless steel divider, centered between the
response levers and below the stimulus lights,
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extended 8 cm into the chamber. Experimen-
tal control was provided by an IBM PS/2
computer located in an adjoining room and
programmed with Med-PC (Med-Associates,
Georgia, VT) software.
Each monkey wore a Teflon mesh jacket
(Lomir, Quebec, Canada) connected to a flex-
ible stainless-steel spring tether attached to the
rear of the cage. Monkeys had been implanted
previously with indwelling intravenous cathe-
ters in an internal or external jugular, or
femoral vein, under ketamine (10 mg/kg, IM)
and xylazine (2 mg/kg, IM) anesthesia. Cathe-
ters were run subcutaneously from the site of
implantation to an exit site in the middle of
the back. Tubing was then fed through the
steel spring tether and passed to the outside
rear of the cage where it was connected to
a stock solution of remifentanil (either 0.4 mg/
kg/ml or 1.2 mg/kg/ml) and additional in-
fusion lines that passed through the rollers of
two infusion pumps. Different doses were
arranged by manipulating the speed of the
two pumps. Operation of one pump delivered
0.15 ml solution per s. Operation of the other
delivered 0.05 ml solution per s. Injections
were always 5 s in duration. When the stock
solution was 0.4 mg/kg/ml remifentanil, oper-
ation of the faster pump resulted in a delivery
of 0.3 mg/kg/inj (0.4 mg/kg/ml 3 0.15 ml/s
3 5 s) and operation of the slower pump
delivered 0.1 mg/kg/inj. When the stock solu-
tion was prepared at 1.2 mg/kg/ml, doses of
0.9 and 0.3 mg/kg/inj were arranged.
General Procedure
Two sessions were conducted each day, one
beginning at 10 a.m. and the other beginning
at 4 p.m. The onset of stimulus lights signaled
the beginning of the session and all stimulus
lights were turned off at the end of the session.
A discrete-trials procedure was employed.
Sessions lasted until 60 trials had been
completed or 2 hr had elapsed, whichever
came first.
At the start of each trial the stimulus lights
above the two levers were illuminated red. One
press on either lever (choice) turned off both
red lights for 0.5 s, following which the light
above the selected lever was re-illuminated
red. Completion of an FR on the selected lever
resulted in a 5-s injection of remifentanil.
During injections, the red light above the
selected lever was turned off and the center
light was illuminated green. Trials were sepa-
rated by a 60-s ITI during which all stimulus
lights were turned off.
We will refer to the FR requirements and
doses associated with the two alternatives as
a comparison. For example, one comparison
consisted of choice between 0.3 mg/kg/inj (FR
30; left lever) and 0.1 mg/kg/inj (FR 30; right
lever). When monkeys chose one alternative
on greater than 90% of the trials, the
consequences of responding on the two levers
were reversed. We usually conducted two to
five lever reversals in each comparison. In a few
cases where monkeys did not exhibit a nearly
exclusive preference for one alternative, lever
reversals were not conducted because monkeys
sampled both alternatives. Rather, compari-
sons were conducted for a minimum of 10
sessions and until obtained choice proportions
were judged to be stable using a visual
criterion of no consistent session-to-session
trend.
The comparisons are grouped into three
phases. The phases were not conducted
sequentially, although most comparisons in
Phase 1 were conducted prior to Phases 2 and
3. Some comparisons were replicated to assess
for possible order effects. Table 1 shows the
comparisons comprising each phase, the order
in which they were conducted, and the FR,
dose, and resulting unit price of each alterna-
tive. In comparisons investigating two different
doses, also shown is the relative price (unit
price of the larger-dose alternative divided by
the unit price of the smaller-dose alternative).
Phase 1: Choice between Alternatives across
Unit Prices
The purpose of Phase 1 was three-fold. First,
we determined if the monkeys would select the
larger dose of remifentanil (0.3 mg/kg/inj)
over the smaller dose (0.1 mg/kg/inj) when
both were available according to the same
FR (Comparisons 1 and 2). Second, we de-
termined if the monkeys would choose the
smaller-FR alternative when both alternatives
produced 0.1 mg/kg/inj (Comparison 3). This
comparison also assessed if the smaller-dose
alternative functioned as a reinforcer. Third,
we assessed choice across a range of unit
prices. In some comparisons the larger-dose
alternative was cheaper (Comparisons 1, 2,
and 4). The smaller-dose alternative was
cheaper in others (Comparisons 5, 6, and 7).
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In Comparison 8, the alternatives were equally
priced. Comparison 6 was one of the last
comparisons investigated in the experiment,
conducted after Phases 2 and 3.
Phase 2: Choice between Equally Priced Alternatives
Table 1 also shows the 15 comparisons
comprising Phase 2; the alternatives in each
comparison were equally priced. In Compar-
isons 9-16, doses of 0.3 and 0.1 mg/kg/inj
remifentanil were employed. Comparisons 17-
23, conducted after exposure to Phase 3,
assessed choice between 0.9 and 0.3 mg/kg/
inj. The comparisons are numbered in order
of ascending FR. Comparisons were not con-
ducted in systematic order. We stopped in-
creasing the FR when monkeys reliably chose
the smaller-dose alternative or exhibited no
preference. For Monkey 3603, we generally
conducted more determinations per compar-
ison (three to seven). This monkey experi-
enced these comparisons first and we wanted
to assess the consistency of preference across
multiple lever reversals. Monkey 3600 initially
was exposed to Comparison 15. When we
increased the FR (Comparison 16), respond-
Table 1
Order and description of each comparison. For each comparison the FR requirement, dose, and
resulting unit price of each alternative are shown. Also shown is the relative price (larger-dose
alternative / smaller-dose alternative). Absolute prices (and relative prices in Phase 3) have been
rounded to the nearest whole number.
Phase Comp.
Order Alt. 1 Alt. 2 Unit price Price
3572 3600 3603 FR Dose FR Dose Alt. 1 Alt. 2 (L/S)
1 1 1 1 1 30 0.3 30 0.1 100 300 0.3
2 6 7 7 100 0.3 100 0.1 333 1000 0.3
3 2 4 4 10 0.1 30 0.1 100 300
4 4 5 2 10 0.3 30 0.1 33 300 0.1
5 3 6 6 30 0.1 100 0.3 300 333 1.1
6 22 29 31 30 0.1 200 0.3 300 667 2.2
7 5 2 3 30 0.1 300 0.3 300 1000 3.3
8 7 3 5 100 0.1 300 0.3 1000 1000 1
2 9 12 31 14 2 0.1 6 0.3 20 20 1
10 9 32 9 4 0.1 12 0.3 40 40 1
11 19 33 12 8 0.1 24 0.3 80 80 1
12 8 34 8 16 0.1 48 0.3 160 160 1
13 20,32 35 10 32 0.1 96 0.3 320 320 1
14 21 36 13 64 0.1 192 0.3 640 640 1
15 10 8,37 11 128 0.1 384 0.3 1280 1280 1
16 11 14 256 0.1 768 0.3 2560 2560 1
17 28 21 25 2 0.3 6 0.9 7 7 1
18 16 23 4 0.3 12 0.9 13 13 1
19 31 15 22 16 0.3 48 0.9 53 53 1
20 29 17 24 32 0.3 96 0.9 107 107 1
21 30 18 64 0.3 192 0.9 213 213 1
22 19 128 0.3 384 0.9 427 427 1
23 20 256 0.3 768 0.9 853 853 1
3 24 13 38 15 2 0.1 12 0.3 20 40 2
25 14 39 16 2 0.1 18 0.3 20 60 3
26 15 40 17 2 0.1 24 0.3 20 80 4
27 16,33 9 18 2 0.1 30 0.3 20 100 5
28 17,34 10,41 19 2 0.1 60 0.3 20 200 10
29 18,35 11,30 20 2 0.1 120 0.3 20 400 20
30 36 12,42 21 2 0.1 240 0.3 20 800 40
31 37 13,43 2 0.1 480 0.3 20 1600 80
32 27 22 26 2 0.3 12 0.9 7 13 2
33 23 27 2 0.3 18 0.9 7 20 3
34 26 24 28 2 0.3 24 0.9 7 27 4
35 25 25 29 2 0.3 30 0.9 7 33 5
36 24 26 30 2 0.3 60 0.9 7 67 10
37 23 27 2 0.3 120 0.9 7 133 20
38 28 2 0.3 240 0.9 7 267 40
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ing was not maintained; these data are not
included in the results. This monkey then
experienced comparisons in Phase 3 before
returning to Phase 2, where responding was
maintained in Comparison 16. For Monkeys
3572 and 3600, some comparisons using the
smaller doses were conducted or replicated
after exposure to the larger doses to assess for
possible order effects.
Phase 3: Choice between a Constant-Priced
Smaller-Dose Alternative and an Escalating-Priced
Larger-Dose Alternative
In Phase 3, the smaller-dose alternative
always was available according to an FR 2. We
increased the FR associated with the larger-
dose alternative as follows: 12, 18, 24, 30, 60,
120, 240, 480. Not all monkeys experienced all
comparisons. Comparisons usually were con-
ducted in ascending order (the most notable
exceptions are Comparisons 32-37, which were
conducted in descending order for Monkey
3572), and we stopped increasing the FR
associated with the larger-dose alternative
when monkeys reliably chose the smaller-dose
alternative. Table 1 also shows the 15 compar-
isons comprising Phase 3. In Comparisons
24-31, choice between 0.3 and 0.1 mg/kg/inj
remifentanil was investigated. Comparisons 32-
38 investigated choice between 0.9 and 0.3 mg/
kg/inj and mostly were conducted after com-
parisons investigating the smaller doses. For
Monkeys 3572 and 3600, some comparisons
using the smaller doses were conducted or
replicated after exposure to the larger doses.
Monkey 3603 received only one determination
in Component 28; this was an oversight.
RESULTS
For each comparison, the total number of
determinations (the initial exposure plus lever
reversals, including replicated comparisons)
conducted, the mean number of sessions
required for near-exclusive choice to develop,
and the mean response rate (resp/s) for each
comparison are shown in the Appendix. Re-
sponse rates are based on the final session in
each determination, collapsed across lever
reversals, and were calculated using the time
to complete the FR after an alternative was
selected. Unfortunately, trial-by-trial latencies
to select an alternative were not collected.
Unless otherwise noted, subsequent analyses
of choice are based on the final session in each
determination (where one alternative was
chosen on .5 90% of the trials), collapsed
across lever reversals.
Phase 1
All monkeys developed near-exclusive
choice of the larger-dose alternative when the
comparison differed only in terms of drug
dose (Comparisons 1 and 2), although Mon-
key 3572 required more sessions before near-
exclusive choice developed in Comparison 1.
Monkeys also developed near-exclusive choice
of the smaller-FR alternative when dose was
held constant (Comparison 3). The fact that
responding was maintained in Comparison 3
demonstrates that 0.1 mg/kg/inj functioned as
a reinforcer. The number of trials completed
was determined by the FR associated with the
selected alternative and was not dose depen-
dent. When the FR was 100 or less, monkeys
usually completed all 60 trials. At larger FR
requirements, monkeys usually completed
between 40 and 50 trials.
Figure 1 shows the mean percent choice of
the larger-dose alternative across all compar-
isons in Phase 1 (excluding Comparison 3, in
which only the smaller dose was available).
Choice is plotted as a function of the relative
price of the larger-dose alternative (unit price
of the larger-dose alternative / unit price of
the smaller-dose alternative). Results have
been collapsed across Comparisons 1 and 2
because relative price is identical. Error bars
represent standard deviations.
Fig. 1. Phase 1. Mean percent choice (and standard
deviation) of the larger-dose alternative as a function of
relative price (unit price of the larger-dose alternative/
unit price of the smaller-dose alternative).
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Monkeys 3572 and 3600 preferred the
larger-dose alternative in all but one compar-
ison, even when it was more expensive. Only in
Comparison 7 (where the larger-dose alterna-
tive was 3.3 times that of the unit price for the
smaller-dose alternative) were these monkeys
sensitive to differences in unit price.
Monkey 3603 selected the lower unit priced
alternative in all comparisons except Compar-
ison 5 where the smallest programmed differ-
ence in unit prices was arranged. Although this
suggests that this monkey preferred the
cheaper alternative, the fact that in Compar-
ison 8 (equal unit prices) the smaller-dose
alternative was strongly preferred suggests that
this monkey simply avoided large FR require-
ments. As shown in Figure 2, this monkey
chose the larger-dose alternative only when it
was available at FR 100 or less.
Phase 1 arranged one comparison in which
the two alternatives were equally priced (Com-
parison 8). In addition, the prices were almost
identical in Comparison 5. All the monkeys
preferred the larger-dose alternative in Com-
parison 5, and two of the three monkeys
preferred the larger-dose alternative in Com-
parison 8. Phase 2 provides a parametric
investigation of choice when the two alter-
natives were equally priced.
Phase 2
Figure 3 shows the mean percent choice of
the larger-dose alternative as a function of the
FR programmed on that alternative in Phase 2;
the smaller-dose FR value was always was one-
third that of the larger-dose. All three monkeys
demonstrated near-exclusive choice of the
larger dose across a range of increasing FR
requirements. With respect to comparisons
investigating choice between 0.3 and 0.1 mg/
kg/inj (circles), Monkey 3572 developed
a lever bias at FR 256/768 (Comparison 16),
selecting the left lever regardless of the
Fig. 2. Phase 1 (Monkey 3603). Mean percent choice
(and standard deviation) of the larger-dose alternative
as a function of the response-requirement associated
with it.
Fig. 3. Phase 2. Mean percent choice (and standard
deviation) of the larger-dose alternative as a function of
the FR programmed on that alternative. The response
requirement associated with the smaller-dose alternative
was one-third that of the larger-dose alternative. Circles
represent comparisons employing 0.3 and 0.1 mg/kg/inj.
Squares represent comparisons employing 0.9 and 0.3 mg/
kg/inj.
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alternative associated with it. Monkey 3600
chose both alternatives about equally at FR
256/768. For this monkey, when we increased
the FR requirements further, responding was
not maintained and these data are not
reported. Monkey 3603 chose the smaller-dose
alternative at FR 128/384. We will term the
switch from selecting the larger-dose alterna-
tive to selecting the smaller-dose alternative as
a preference reversal.
When larger doses were investigated (Fig-
ure 3, squares), Monkeys 3600 and 3603
continued to choose the larger-dose alterna-
tive (0.9 mg/kg/inj) across a range of increas-
ing ratios. At greater FR requirements, a pref-
erence reversal was obtained for these
monkeys. Monkey 3572 was indifferent across
a wide range of FR values, though preference
for the smaller-dose alternative was observed at
FR 64/192. For all monkeys, preference for
the smaller-dose alternative emerged at smal-
ler ratio values relative to choices between 0.3
and 0.1 mg/kg/inj.
Figure 4 shows the mean number of trials
completed as a function of the FR pro-
grammed on the larger-dose alternative. Open
symbols represent comparisons in which the
smaller-dose alternative was preferred, or
comparisons in which neither alternative was
preferred.
With respect to choice between 0.3 and
0.1 mg/kg/inj (circles), the monkeys complet-
ed all 60 trials at smaller response require-
ments. Subsequently, the number of trials
completed decreased as a function of the FR.
When Monkey 3603 reversed preference and
selected the smaller-dose alternative, the num-
ber of trials completed increased. Monkeys
3572 and 3600 did not reliably select either
alternative at FR 256/768.
When larger doses were investigated
(squares), the monkeys completed 50-60 trials
at the smallest FR. Trials completed decreased
at smaller ratios relative to comparisons in-
vestigating choice between 0.3 and 0.1 mg/kg/
inj. Trials completed increased when the
monkeys reversed preference and selected
the smaller-dose alternative. These results
suggest that 0.9 mg/kg/inj remifentanil sup-
pressed responding.
Phase 3
In Phase 3 the smaller-dose alternative
always was available according to an FR 2 and
the unit price of the larger dose always
exceeded that of the lower-dose alternative.
Figure 5 shows the mean percent choice of the
larger-dose alternative as a function of its FR
requirement. Results from Comparisons 9 and
17 of Phase 2 also are shown because the
smaller-dose was available on an FR 2.
Fig. 4. Phase 2. Mean number of trials completed as
a function of the response requirement programmed on
the larger-dose alternative. Error bars represent standard
deviations. Circles represent comparisons employing 0.3
and 0.1 mg/kg/inj; squares represent comparisons employ-
ing 0.9 and 0.3 mg/kg/inj. Open symbols represent
comparisons in which the larger-dose alternative was
not preferred.
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In the smaller dose pairing (0.3 v. 0.1;
circles) all the monkeys selected the larger-
dose alternative more frequently despite its
being the higher-priced alternative. Monkeys
3572 and 3600 selected the larger dose nearly
exclusively even when its price was 40 times
that of the smaller-dose alternative, whereas
Monkey 3603 preferred the larger dose when it
was 20 times more expensive than the smaller-
dose alternative (Table 1). At larger FR values
(FR 240 and 480), preference reversed to the
smaller-dose alternative.
The squares in Figure 5 represent choice
between doses of 0.9 and 0.3 mg/kg/inj.
Again, Monkeys 3600 and 3603 preferred the
larger-dose, more expensive alternative, but
a preference reversal occurred at lower ratios
(FR 240 and 60, respectively) relative to the
smaller doses. Similar to the results obtained
in Phase 2 with larger doses, Monkey 3572 did
not exhibit a consistent dose preference across
the FR 6–24 range. This monkey reliably
selected the smaller-dose alternative when
the larger-dose alternative produced drug
according to an FR 30 schedule and thereafter.
Figure 6 shows the mean number of trials
completed as a function of the FR pro-
grammed on the larger-dose alternative. In
the smaller-dose pairing (circles) the monkeys
completed all 60 trials across a range of
increasing FR requirements. Trials completed
decreased at larger FR requirements. When
larger doses were employed, trials completed
decreased at lower ratios relative to the smaller
doses. When monkeys selected the smaller-
dose alternative (available according to an FR
2), they completed all (or almost all) 60 trials.
As shown in Figures 3 and 5 (Phases 2 and
3), Monkey 3572 never strongly preferred the
larger-dose alternative in the larger-dose pair-
ing (0.9 and 0.3 mg/kg/inj). In light of these
results, we wanted to determine if this monkey
would reliably choose the larger- over the
smaller-dose alternative when both were avail-
able at FR 30. As before, this monkey did not
reliable select the larger-dose alternative,
suggesting problems with dose discrimination
in the larger-dose pairing for this monkey.
DISCUSSION
According to unit-price predictions of
choice, when the same commodity is available
at different prices on FR schedules, exclusive
choice should develop for the cheaper alter-
native. The results obtained using the m-opiod
agonist remifentanil do not support this
hypothesis. Across a wide range of prices,
monkeys almost always chose the larger-dose
alternative, even if it was the more expensive
alternative. This effect can be seen most
dramatically in Figure 5 (0.3 vs. 0.1 mg/kg/
inj), where monkeys preferred the larger-
dose alternative available at an FR 120 or
Fig. 5. Phase 3. Mean percent choice (and standard
deviation) of the larger-dose alternative as a function of its
programmed response requirement. The response re-
quirement associated with the smaller-dose alternative
was held constant at an FR 2.
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240 over the smaller-dose alternative available
at an FR 2.
Madden et al. (2000) reported that at
relatively low unit prices, human smokers
preferred a larger number of cigarette puffs
over a smaller number of puffs, even if the
larger-puff alternative was the slightly more
expensive alternative. At relatively high unit
prices, a preference reversal occurred and
subjects chose the smaller-puff alternative.
The results obtained in the present study are
consistent with these results. Our results also
are consistent with those reported by Ander-
son and Woolverton (2003) in which rhesus
monkeys preferred a more delayed but larger
dose of cocaine over a more immediate
smaller dose across a range of delays. In-
terestingly, in both our study and Anderson
and Woolverton’s, employing larger overall
doses of drug attenuated the larger-dose
preference. These results are inconsistent,
however, with findings obtained by Foster
and Hackenberg (2004), who investigated
pigeons’ choice between food alternatives
available at different FR requirements but
equal unit prices. Preference for the smaller-
magnitude reinforcer available at a smaller
response requirement was obtained. This
discrepancy may reflect procedural differ-
ences, species differences, or differences be-
tween reinforcers (food versus drug).
Madden et al. (2000) sought to account for
systematic deviations from a strict unit-price
interpretation of choice by expanding the
unit-price equation to include the handling
costs associated with reinforcer consumption
(e.g., removing the cigarette, lighting it,
placing it into a plastic holder, etc.) and the
obtained delay to reinforcement. Madden et
al. postulated that the value of the reinforcer
(V) is degraded according to Mazur’s (1984)
hyperbolic discounting function. Incorporat-
ing the discounted value of the reinforcer and
associated handling costs (H), Madden et al.
reported that a modified unit-price equation,
Unit Price ~ (FR z H)=V, ð2Þ
was somewhat accurate in predicting choice.
In Madden et al.’s study, the handling costs
were the same regardless of whether the
larger- or smaller-puff alternative was selected.
Therefore the relative handling costs (han-
dling costs per puff) were greater for the
smaller-puff alternative. At low prices (and
brief delays) differences in handling costs
resulted in preference for the larger-puff
alternative. At high prices (and longer delays)
the handling costs relative to the costs associ-
ated with the increasing FR became minimal.
Additionally, the value of the more-delayed
larger-puff alternative was sufficiently degrad-
ed to result in preference for the smaller-puff
alternative.
Although our main findings are similar to
those obtained by Madden et al. (2000), they
Fig. 6. Phase 3. Mean number of trials completed as
a function of the response requirement programmed on
the larger-dose alternative. See Figure 4 for more details.
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cannot be predicted by this modified unit-
price equation. First, there were no handling
costs in our experiment because intravenous
drug delivery does not require a consummatory
response. Second, although degrading the
value of the (more delayed) larger-dose
alternative may result in a preference reversal,
it cannot account for the preference for the
more expensive larger-dose alternative, partic-
ularly in Phase 3. Degrading the value of the
larger-dose alternative by incorporating delay
as a cost variable would only increase the cost
of the already more expensive (yet preferred)
larger-dose alternative.
There are several possible reasons why our
results are inconsistent with unit-price predic-
tions of choice. Demand-function analysis has
shown that for some drugs (e.g., cocaine) the
smallest reinforcing dose is more elastic than
larger doses (Hursh & Winger, 1995). Al-
though Hursh and Winger demonstrated that
this is not the case with remifentanil, they
employed a 10-s timeout following drug de-
livery whereas we used a 60-s ITI. To the extent
that drug accumulation is necessary for scalar
equivalence to exist between drug doses,
perhaps our use of the ultra-short acting
opioid combined with a long ITI contributed
to the larger-dose preference.
Constraints imposed by the use of a discrete-
trials procedure also could have contributed to
the larger-dose preference. In Madden et al.’s
(2000) study, sessions were time-based. Smok-
ers could earn the same total number of puffs
by selecting the larger-puff alternative or
selecting the smaller-puff alternative and
completing more ratios. In our study, the
same level of remifentanil consumption could
not be maintained by selecting the smaller-
dose alternative and completing three times as
many trials (there was a 60-trial limit). Choos-
ing the larger-dose alternative, then, was the
only way to defend consumption against
increasing FR requirements. Perhaps monkeys
preferred the larger-dose alternative (even if it
was more expensive) at prices where remifen-
tanil demand was inelastic and total consump-
tion could be defended.
The demand function in Figure 7 shows
remifentanil consumption plotted as a func-
tion of unit price. These results were obtained
from a previous study in our laboratory that
investigated doses of 0.03, 0.1, and 0.3 mg/kg/
inj (Ko et al., 2002). The dashed lines indicate
the consumption limitations imposed by the
current experiment. For example, if 0.3 mg/
kg/inj was selected on all 60 trials, total
consumption would equal 18 mg/kg/session.
Note that this amount is substantially less than
the remifentanil consumed at low prices in
a fixed 2-hr session in the experiment by Ko et
al. We hypothesize that across a range of
prices, monkeys defended this (already con-
strained) level of consumption by choosing
the larger-dose alternative. At prices where
remifentanil demand is elastic, consumption
decreases (fewer trials are completed) and at
some price consumption approaches a level
(6 mg/kg/session) that could be obtained by
near-exclusive choice of the smaller-dose
alternative (shown by the arrow at a unit price
of 1000). At this point the preference reversal
may occur. Consistent with our results, Fig-
ure 7 shows that the preference reversal
should occur at lower prices when larger doses
are investigated (0.9 and 0.3 mg/kg/inj).
Superimposed on the demand function
obtained by Ko et al.(2002), average session
consumption from Phases 2 and 3 are pre-
sented in Figures 8 and 9. (The results
obtained from Phase 1 are not easily conducive
to this type of presentation because the unit
prices associated with both alternatives varied
simultaneously and disproportionately across
comparisons.) Figure 8 shows the mean con-
sumption as a function of unit price in Phase
2. Circles represent comparisons investigating
Fig. 7. Remifentanil consumption as a function of unit
price. The results are from those reported by Ko et
al.(2002). Superimposed on this demand function are the
consumption constraints imposed by the present pro-
cedure. Each dashed line shows the total consumption for
exclusive choice of 0.1, 0.3, and 0.9 mg/kg/inj. The arrows
represent the hypothetical point at which choosing either
dose alternative results in equivalent total consumption.
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choice between 0.3 and 0.1 mg/kg/inj.
Squares represent comparisons investigating
the larger doses (results from Monkey 3572
have been omitted because this monkey did
not reliably discriminate these doses). The
functions with solid symbols represent com-
parisons in which the larger-dose alternative
was preferred. The last point on these func-
tions shows consumption in the comparison
that ultimately produced the preference re-
versal before near-exclusive preference for the
smaller-dose alternative developed. In most
cases this consumption measure came from
one of the first sessions in the comparison
when the larger-dose alternative was still pre-
ferred. This point is meant to serve only as an
estimate of the total consumption if the larger-
dose alternative had been chosen exclusively;
Fig. 8. Average total session consumption from each
comparison in Phase 2, superimposed on the remifentanil
demand function described in Figure 7. Each dashed line
shows the total consumption for exclusive choice of 0.1,
0.3, and 0.9 mg/kg/inj remifentanil. Circles represent
comparisons investigating choice between 0.3 and
0.1 mg/kg/inj; squares represent choice between 0.9 and
0.3 mg/kg/inj. Open symbols represent comparisons in
which either the smaller-dose alternative was preferred or
indifference was obtained. The last point on the closed
function represents an estimate of the total session
consumption in this comparison before preference for
the smaller-dose alternative (or indifference) developed
(see text for more details).
Fig. 9. Average daily consumption from each compar-
ison in Phase 3. See Figure 8 for more details.
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it probably overestimates consumption be-
cause it includes intake from additional
smaller-dose deliveries. Average consumption
when the smaller-dose alternative was pre-
ferred is shown by the open symbols. There
were two exceptions to these calculations, both
involving choice between 0.3 and 0.1 mg/kg/
inj at the points corresponding to the prefer-
ence reversal. Monkey 3600 responded on
both levers in this comparison, and choice
proportions approximated 0.5. We calculated
consumption during the session in which this
monkey selected the larger-dose alternative
the most times (closed circle) and the session
in which the smaller-dose alternative was
selected the most times (open circle). Monkey
3572 developed a near-exclusive preference
for the left lever. When left-lever pressing
produced the larger-dose alternative, con-
sumption is shown by the closed circle, and
when the smaller-dose alternative, by the open
circle.
With respect to choice between the smaller
doses (circles), the constraints imposed by the
discrete-trials procedure resulted in markedly
lower consumption relative to that obtained by
Ko et al. (2002). Across a range of prices, all
monkeys consumed slightly less than 18 mg/
kg/session. Consumption decreased with fur-
ther increases in price. For Monkey 3603,
consumption on the elastic portion of the
function was similar to that obtained by Ko et
al. For the other two monkeys, remifentanil
demand was more inelastic than that obtained
by Ko et al. These differences could be
attributed to differences in the doses of
remifentanil assessed, differences in the dura-
tion of the timeout (or ITI) following the drug
injection, or simply may reflect differences
among individual monkeys.
Of critical importance is the total consump-
tion at the point where the larger-dose
alternative was no longer preferred. Near-
exclusive choice of the smaller-dose alternative
resulted in a similar level of consumption
relative to the estimated consumption had the
larger-dose alternative been selected. The
same finding was obtained when larger doses
were employed, and the point at which
obtained consumption was almost identical
regardless of dose selected occurred at lower
overall prices.
Figure 9 shows the average session consump-
tion from Phase 3 plotted as a function of the
unit price of the larger-dose alternative. Overall,
the results are similar to those shown in
Figure 8. At the point of the preference reversal,
total consumption when the smaller-dose alter-
native was selected (open symbols) approximat-
ed the estimated consumption obtained when
the larger-dose alternative was preferred.
The results from the larger-dose compar-
isons (squares) for Monkey 3603 represent the
largest deviation from this general finding.
This monkey selected the smaller-dose alter-
native (open square) when choice of the
larger-dose alternative (closed square) would
have produced more drug. These results must
be interpreted cautiously because this monkey
never actually preferred the larger-dose alter-
native in any session during this comparison
(Comparison 36). The last closed square shows
intake during the session in which the larger-
dose alternative was chosen the most times. In
this session, the larger-dose alternative was
selected 11 times and the smaller-dose alter-
native was selected 49 times. Therefore, the
consumption shown by the last closed square is
not an accurate estimate of the total intake
that would have been obtained if this monkey
chose the larger-dose alternative exclusively.
Bickel, Marsch, and Carroll (2000) pro-
posed that, under some circumstances, exam-
ining demand functions for two different
commodities may yield accurate choice pre-
dictions. Our results suggest that demand
functions may be useful in predicting choice
between the same drug available at different
prices. At prices where demand is inelastic,
subjects preferred the larger-dose alternative,
even if it was more expensive. The preference
reversal occurred on the elastic portion of the
demand function. Future research, in which
demand functions for each dose are obtained
prior to the choice situation, may determine if
the preference reversal occurs at the point at
which demand switches from inelastic to
elastic, or the point at which choosing the
more expensive larger-dose alternative does
not result in increased total consumption
relative to the smaller-dose alternative.
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APPENDIX
Total number of determinations conducted, the mean number of sessions (per determination)
required for near-exclusive choice to develop, and the mean response rate (resp/s) for each
comparison. Standard deviations are shown in parentheses. (See Table 1 for dose and FR
response requirements used in each comparison.)
Phase Monkey Comp. Det. Sessions Resp/s
1 3572 1 5 14.0 (5.3) 1.9 (1.8)
2 4 3.2 (1.3) 2.6 (1.8)
3 5 12.2 (5.9) 3.9 (1.3)
4 3 8.0 (3.0) 3.4 (2.8)
5 5 5.2 (1.2) 3.4 (1.8)
6 3 2.7 (0.5) 2.6 (1.7)
7 4 8.0 (8.7) 4.1 (1.9)
8 4 10.5 (5.6) 2.9 (2.1)
3600 1 5 2.2 (0.4) 3.7 (1.1)
2 7 1.1 (0.3) 4.0 (0.7)
3 6 7.0 (2.8) 4.6 (1.2)
4 5 4.6 (1.5) 4.7 (0.9)
5 6 1.7 (0.7) 4.3 (0.7)
6 3 5.7 (4.5) 3.0 (1.2)
7 5 5.8 (4.4) 3.7 (1.2)
8 3 4.3 (3.3) 3.4 (1.0)
3603 1 4 3.2 (1.9) 2.9 (0.9)
2 5 1.2 (0.4) 2.6 (1.0)
3 6 4.2 (4.4) 2.9 (0.9)
4 4 1.7 (0.4) 3.1 (1.0)
5 4 4.7 (3.3) 3.0 (1.0)
6 3 1.7 (0.9) 2.1 (1.2)
7 4 1.5 (0.5) 3.2 (0.8)
8 6 1.8 (1.9) 2.3 (0.8)
2 3572 9 3 1.7 (0.5) 2.5 (1.9)
10 3 9.3 (7.6) 2.8 (2.3)
11 3 4.7 (1.2) 3.2 (2.6)
12 3 3.0 (0.8) 2.9 (2.4)
13 4 2.2 (0.8) 3.9 (1.9)
14 3 2.0 (0.8) 3.0 (1.6)
15 3 5.0 (3.2) 3.1 (1.6)
16 3 7.3 (2.0) 3.5 (1.6)
17 1 18.0 (0.0) 2.7 (2.6)
19 2 10.0 (0.0) 2.2 (2.1)
20 3 11.3 (1.2) 3.1 (1.7)
21 2 5.0 (2.0) 3.2 (1.6)
3600 9 2 3.5 (1.5) 3.3 (1.6)
10 3 1.7 (0.9) 2.1 (1.4)
11 2 3.0 (1.0) 2.5 (1.1)
12 2 2.0 (1.0) 2.4 (1.3)
13 2 1.0 (0.0) 2.7 (1.1)
14 3 3.0 (0.8) 2.6 (1.3)
15 6 7.2 (3.4) 3.3 (1.0)
16 1 16.0 (0.0) 3.1 (1.0)
17 4 5.5 (3.6) 2.2 (1.7)
18 2 2.5 (0.5) 1.5 (1.6)
19 3 3.3 (0.5) 1.4 (1.3)
20 3 2.3 (1.9) 2.0 (1.4)
21 3 2.0 (0.8) 2.4 (1.2)
22 3 3.7 (2.5) 2.6 (0.8)
23 3 5.3 (2.0) 3.3 (0.8)
3603 9 5 1.4 (0.8) 2.8 (1.2)
10 5 1.0 (0.0) 2.5 (1.0)
11 5 1.2 (0.4) 2.8 (0.9)
12 7 1.4 (1.0) 2.3 (0.8)
13 5 1.2 (0.4) 2.5 (0.7)
14 5 1.4 (0.8) 2.3 (0.8)
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Phase Monkey Comp. Det. Sessions Resp/s
2 3603 15 5 2.6 (1.6) 2.5 (0.9)
17 3 3.0 (2.8) 2.9 (1.3)
18 4 2.5 (0.5) 2.5 (1.2)
19 4 2.0 (1.0) 2.5 (0.9)
20 4 1.2 (0.4) 2.6 (0.7)
3 3572 24 3 2.7 (0.9) 3.0 (2.3)
25 2 3.5 (1.5) 3.2 (2.5)
26 3 9.0 (5.7) 2.5 (2.4)
27 4 4.2 (3.4) 2.3 (2.5)
28 6 6.5 (5.0) 2.4 (2.1)
29 4 2.2 (0.8) 3.2 (1.6)
30 2 1.5 (0.5) 3.9 (1.6)
31 2 4.5 (1.5) 8.6 (2.9)
32 4 9.2 (4.9) 2.5 (3.0)
34 1 14.0 (0.0) 2.0 (2.7)
35 2 2.5 (0.5) 3.0 (3.3)
36 2 8.0 (5.0) 2.9 (3.3)
37 2 4.0 (3.0) 4.0 (3.6)
3600 24 2 1.5 (0.5) 3.6 (1.6)
25 2 1.0 (0.0) 3.5 (1.7)
26 3 2.7 (1.7) 2.2 (1.6)
27 3 2.0 (1.0) 3.9 (0.8)
28 5 2.0 (1.2) 3.0 (1.3)
29 6 2.2 (1.3) 2.9 (0.9)
30 7 2.3 (2.2) 3.2 (0.9)
31 6 2.0 (1.0) 5.9 (3.7)
32 3 3.0 (2.2) 1.1 (1.2)
33 5 2.0 (0.6) 1.4 (1.3)
34 2 1.0 (0.0) 1.3 (1.0)
35 2 2.5 (1.5) 1.3 (1.0)
36 2 1.5 (1.5) 1.5 (1.0)
37 3 6.0 (4.5) 1.9 (0.8)
38 3 3.0 (0.0) 6.1 (3.9)
3603 24 2 1.0 (0.0) 2.9 (1.1)
25 2 1.0 (0.0) 3.1 (0.9)
26 3 1.3 (0.5) 3.3 (0.9)
27 2 1.0 (0.0) 3.2 (0.9)
28 1 2.0 (0.0) 2.6 (0.8)
29 2 1.0 (0.0) 2.8 (0.8)
30 3 2.0 (0.0) 3.3 (2.9)
32 3 1.0 (0.0) 3.0 (0.8)
33 3 1.7 (0.5) 3.1 (0.9)
34 3 1.0 (0.0) 2.7 (0.9)
35 3 1.3 (0.5) 2.5 (0.8)
36 5 2.5 (1.2) 4.4 (3.2)
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